We aim to achieve industry-leading growth by investing effectively in our business, developing our people, and striving for innovation.

We commit to scientific and technical excellence by developing new products that meet the needs of patients, payers, and consumers.
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>2</td>
</tr>
<tr>
<td>GSK</td>
<td>3</td>
</tr>
<tr>
<td>UNC Eshelman School of Pharmacy</td>
<td>6</td>
</tr>
<tr>
<td>Fellowships</td>
<td>8-13</td>
</tr>
<tr>
<td>• US Medical Affairs</td>
<td>8</td>
</tr>
<tr>
<td>• Global Regulatory Affairs</td>
<td>10</td>
</tr>
<tr>
<td>• Pharmacokinetics/Pharmacodynamics</td>
<td>12</td>
</tr>
<tr>
<td>UNC GSK Fellowship Alumni</td>
<td>14</td>
</tr>
<tr>
<td>Application and Eligibility</td>
<td>16</td>
</tr>
</tbody>
</table>
The fellowship programs are two years in length, thus enabling fellows to develop a strong scientific foundation in areas of interest and apply practical knowledge in the setting of pharmaceutical drug development. There is an emphasis on ensuring direct contribution to the advancement of the pharmaceutical sciences as related to the field of study.

GSK has a rich history of collaborations with a variety of leading academic institutions through sponsorship of joint fellowship programs.

Fellowships offered by GSK in partnership with UNC Eshelman School of Pharmacy include:

- **US Medical Affairs** (PharmD or PhD)
- **Global Regulatory Affairs** (PharmD, PhD, or MD)
- **Pharmacokinetics/Pharmacodynamics** (PharmD, PhD, or MD)
Today there are millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions of people who suffer from everyday ailments. We want to change this. That's why we are harnessing our scientific and technical know-how, our talented people, our partnerships, and our global reach to develop and manufacture healthcare products for people who need them.

Our mission is to improve the quality of human life by enabling people to do more, feel better, and live longer.

Our DNA

Our strategy

Bring quality, needed healthcare products to as many people as possible, with our scientific and technical know-how and talented people.
Who we are

A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

We have 3 global businesses that discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.

What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our 3 global businesses, scientific and technical know-how and talented people.

Pharmaceuticals

Our Pharmaceuticals business has a broad portfolio of innovative and established medicines with leadership positions in respiratory and HIV. We are strengthening our pipeline through a focus on science related to the immune system, human genetics and advanced technologies.

£17.3bn
Sales turnover 2018

Top 3 sales drivers 2018

- Dolutegravir portfolio
- HIV
- Ellipta portfolio
- Respiratory
- Seretide/Advair
- Respiratory

Vaccines

We are the leading vaccines company in the world, delivering over 2 million vaccine doses every day to people living in over 150 countries. Our portfolio helps protect people throughout their lives. We have recently introduced breakthrough vaccines for shingles and meningitis B.

£5.9bn
Sales turnover 2018

Top 3 sales drivers 2018

- Meningitis
- Paediatric and adult
- Hepatitis
- Paediatric and adult
- Shingles
- Adult

Consumer Healthcare

We are the world’s largest Consumer Healthcare company following our new joint venture with Pfizer. We develop and market a portfolio of consumer-preferred and expert-recommended brands including Sensodyne, parodontax, Poligrip, Advil, Voltaren, Panadol, Centrum, Otrivin and Theraflu.

£7.7bn
Sales turnover 2018

Top 3 selling GSK brands 2018

- Sensodyne
- Oral health
- Voltaren
- Pain relief
- Panadol
- Pain relief

GSK at a glance
How we do it

Everyone at GSK is focused on our 3 long-term priorities:

Innovation
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

Performance
We drive growth and profitability by disciplined investment in our strategic priorities, attracting and developing great people and high quality execution.

Trust
We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer.

34 new medicines in development targeting the patient’s immune system to treat disease (as of May 2019)

No.1
dolutegravir is the most prescribed core agent for HIV treatments worldwide

1st
single dose medicine approved in 60 years for treating relapsing malaria

Our culture
Our values and expectations are at the heart of everything we do and define our culture – so that together we can deliver extraordinary impact for patients and consumers and make GSK a brilliant place to work.

Our values
Patient focus
Transparency
Respect
Integrity

Our expectations
Courage
Accountability
Development
Teamwork

Why we do it
To help people do more, feel better, live longer.
The UNC Eshelman School of Pharmacy, ranked as the #1 pharmacy school in the nation by the US News and World Report 2016, is a nationally recognized leader in progressive pharmaceutical care practice, education, and research.

UNC PARTNERSHIP

The UNC Eshelman School of Pharmacy is part of the University of North Carolina at Chapel Hill, a major research university with a large academic medical center. The School of Pharmacy has specialized research centers pursuing advancements in drug delivery, nanotechnology, cancer treatment, pharmacogenomics, and medication optimization.

The Chapel Hill campus is close to the RTP business region, and several large health systems. It offers a rich blend of culture, entertainment, recreation, fine dining, and some of the best college basketball action in the country.

RESEARCH TRIANGLE PARK (RTP)

UNC anchors one corner of North Carolina's famed RTP which hosts an abundance of pharmaceutical, biotechnology, and healthcare companies. This environment offers opportunities for collaboration in research, education, and patient care with partners in academia, industry, and healthcare.

RTP houses critical GSK roles in US pharmaceuticals and manufacturing functions, as well as Research and Development (R&D) and ViiV Healthcare.

US Medical Affairs fellows gain pharmaceutical industry experience during the second year of the fellowship program at RTP.

"Year after year, I am in awe of our fellows’ initiative and innovation and the unique hands-on learning opportunities afforded to them by the University and GSK."

Jo Ellen Rodgers, PharmD, BCPS, FCCP
UPPER PROVIDENCE (UP) / COLLEGEVILLE

The Upper Providence GSK site, which is the US R&D Hub, is named for its location in Upper Providence Township, Montgomery County, Pennsylvania. It is approximately 30 miles northwest of Center City Philadelphia and approximately 35 miles from Philadelphia International Airport.

Global Regulatory Affairs (GRA) fellows are based out of UP throughout the 2-year duration of the fellowship program. Pharmacokinetics/Pharmacodynamics (PK/PD) fellows relocate to UP after their first year at UNC. At UP, GRA and PK/PD fellows gain hands-on pharmaceutical industry experience in a highly dynamic work environment.

"Each year, for almost four decades, we have an incredible group of fellows, who make a significant contribution to the legacy of our program. These fellows are a reflection of UNC and GSK’s strong long-standing commitment to train and develop the newest generation of pharmaceutical industry professionals."

Robert Dupuis, PharmD, FCCP
US Medical Affairs fellowship

The US Medical Affairs fellowship at GSK provides the practical training and experience needed to successfully obtain a position in the pharmaceutical industry, academia, clinical practice, or Contract Research Organizations.

Fellows will work in a cross-functional matrix team which consists of the US Medical Affairs Lead, therapy area scientific/medical directors, global medical affairs, global clinical safety and pharmacovigilance, regulatory affairs, legal, health outcomes, research and development, and commercial.

Fellowship objectives

- Work closely with US Medical Affairs Leads and Accountable Medical Leads to execute tactics that support the overall medical strategy
- Understand principles of clinical research, apply clinical trial design strategies, and collect and analyze data
- Conduct strategic reviews of the medical literature and the competitive environment to identify data and educational gaps to enhance patient care
- Contribute to US scientific engagement between GSK and external communities to advance the understanding of disease treatment and management
- Participate in the medical review of promotional materials and communicate scientific information to internal and field based colleagues
- Support launch preparations for new medicines and/or new indications or label extensions
Year one

At UNC Eshelman School of Pharmacy, fellows will have the opportunity to

• Review the principles of clinical research, such as Good Clinical Practice (GCP) and gain an understanding of the wellbeing of study subjects, data collection, analysis, and safety reporting
• Apply clinical design strategies, evaluate research designs and study reports, and utilize biostatistical tests
• Develop protocols, recruit and monitor subjects, collect and analyze data, and prepare an academic manuscript

Year two

At GSK within US Medical Affairs, fellows will have the opportunity to

• Understand the decision-making process that healthcare providers and payers follow for drug utilization
• Contribute to the development and execution of US Medical Affairs plans and integrate the voice of the customer including, providers, payers, patients, into a medical affairs strategy
• Gain clinical knowledge and product expertise in a therapeutic area

“The partnership with UNC provides fellows the opportunity to build a solid drug development foundation from a variety of academic learnings and apply acquired knowledge at GSK. Fellows gain an appreciation of the value of scientific engagement between GSK and external communities and make significant contributions that can have a positive impact on patient lives.”

Shelly Lener, PharmD

Program Director

Preceptors

Bryant Tran, PharmD, MS, MBA
Scientific Director, US Medical Affairs, GSK

Laura Sutton, PharmD
Therapeutic Area, Scientific Director, CMO Medical Affairs, GSK

Fellows

Lauren Hothem, PharmD
Second Year Fellow
UNC Eshelman School of Pharmacy

Alexis Williams, PharmD
Second Year Fellow
UNC Eshelman School of Pharmacy

Justin Veeder, PharmD
First Year Fellow
UNC Eshelman School of Pharmacy

Catherine Nguyen, PharmD
First Year Fellow
UNC Eshelman School of Pharmacy
The Global Regulatory Affairs (GRA) fellowship provides practical training and experience in regulatory affairs to help fellows gain expertise in regulatory requirements and strategy pertinent to drug development.
GSK will recruit qualified post-doctoral Regulatory Affairs fellow candidates to support either:

- Therapeutic Groups (Regulatory Strategy)
- Chemistry Manufacturing Controls (CMC) Biopharmaceuticals

During the fellowship, the fellow will work with regulatory leaders to gain hands-on experience and have the opportunity to:

- Develop valuable regulatory strategic skills across all phases of drug development and function as an effective project team member
- Prepare regulatory interaction documents and submission packages and interact with regulatory agencies to guide product development
- Develop and maintain awareness of the regulatory landscape to inform drug development
- Participate in departmental initiatives for process improvements and/or regulatory knowledge management

Candidates should identify which position is of interest.

“Fellows are given the opportunity to utilize the knowledge and leadership skills they have obtained at UNC and gain hands on experience in the pharmaceutical industry at GSK. The program also assists in identifying and developing emerging talent to potentially support the future GSK business. On behalf of GRA, we very much look forward to working with the fellows over the coming years!”

Mark DeSiato

Mark DeSiato
Vice President, Therapeutic Group Regulatory Head, GSK

Kevin Fitzgerald, BSPharm
Senior Director, Delivery Team Lead & Regulatory Expert, Regulatory Transformation RPS, GSK

Ariana Aun, PharmD, RPh
Second Year Fellow
Keck Graduate Institute School of Pharmacy

Kwadwo Yeboah, PharmD
Second Year Fellow
Purdue University

Riddhi Virparia, PharmD
First Year Fellow
Rutgers University

Eric Mui, PharmD
First Year Fellow
University of Wisconsin - Madison

Shivam Patel, PharmD, RAC
Manager, Oncology Therapeutic Group, Global Regulatory Affairs, GSK
The Pharmacokinetics/Pharmacodynamics (PK/PD) fellowship provides practical training and experience needed to successfully obtain a position as a Clinical Pharmacologist in the pharmaceutical industry, academia, or in a clinical setting.

The fellowship emphasizes coursework and hands-on experience focused on the application of population and physiologically-based PK/PD modeling and simulation techniques to guide drug development. Fellows will work on cross-functional teams and contribute to drug development from a clinical pharmacology perspective.

Fellowship objectives

- Understand the nature and relevance of clinical data evaluations relative to drug development
- Design and implement studies to examine drug absorption, drug disposition, pharmacodynamic endpoints and drug interactions in healthy human volunteers or diseased patient populations
- Understand foundational concepts related to population PK/PD and physiologically-based PK modeling and simulation techniques
- Understand important considerations in clinical trial design and the conduct of clinical investigations in specific patient populations (e.g., pediatrics)
- Perform PK/PD and statistical data analysis using relevant software packages
- Prepare a manuscript, seminar and other scholarly vehicles for communication of scientific results
Year one

At UNC Eshelman School of Pharmacy, fellows will have the opportunity to

- Engage in didactic and scholarly training via coursework in population and physiologically-based PK/PD modeling and simulation techniques
- Coordinate and support clinical pharmacology, drug pharmacokinetic and metabolism studies and mathematical modeling with UNC Division of Pharmacotherapy and Experimental Therapeutics (DPET) faculty
- Design, conduct and carry out data analysis of clinical pharmacology studies in the academic setting as part of the learning experience

Year two

At GSK within Clinical Pharmacology Modelling and Simulation (CPMS), fellows will have the opportunity to

- Interact with multi-disciplinary teams to apply state-of-the-art quantitative methodologies to aid the development of compounds in the GSK portfolio; such as population PK/PD analyses, exposure-response, disease progression modeling and clinical trial simulations
- Provide expertise to the design and analysis of first-time-in-human, proof-of-concept, drug-drug interaction or other clinical pharmacology studies
- Contribute to modeling and simulation efforts for quantitative decision making to enhance study design, support candidate selection, provide dose rationale, and/or benchmark against competitor compounds

Program Director

Rajendra Singh, PhD
Director, Clinical Pharmacology Modeling and Simulation, GSK

UNC Preceptor

Daniel Gonzalez, PharmD, PhD
Assistant Professor, Division of Pharmacotherapy and Experimental Therapeutics, UNC

Fellows

Fernando Carreño, PhD
First Year Fellow
Federal University of Rio Grande do Sul

“An academic setting like UNC DPET within Eshelman School of Pharmacy, is a phenomenal learning environment for the fellow to become acquainted with the complex techniques that will aid him/her to succeed at GSK. While at GSK the fellow will be able to seamlessly transition into the work utilizing GSK’s state of the art capabilities in modeling and simulation projects”

Rajendra Singh, PhD
### Employed at GSK

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Fellowship</th>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Pappa</td>
<td>Director, Clinical Development, Chief Scientific and Medical Office, Viiv</td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td>1985-1986</td>
</tr>
<tr>
<td>Karol LaCroix</td>
<td>Team Leader, SERM, Central Safety Department, GSK</td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td>1986-1987</td>
</tr>
<tr>
<td>Linda Clayton</td>
<td>Director, SERM, Central Safety Department, GSK</td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td>1989-1990</td>
</tr>
<tr>
<td>Lynn Henson</td>
<td>Senior Director, SERM, Central Safety Department, GSK</td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td>1990-1992</td>
</tr>
<tr>
<td>Sarah Roberts</td>
<td>Manager, Global Regulatory Affairs, Labeling, GSK</td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td>1998-2000</td>
</tr>
<tr>
<td>Susan Ford</td>
<td>Director, Clinical Pharmacology, GSK</td>
<td>Pharmacokinetics &amp; Pharmacodynamics fellow</td>
<td>2000-2002</td>
</tr>
<tr>
<td>Michael Lim</td>
<td>Director, EPCS, Global Oncology Franchise, GSK</td>
<td>Drug Development fellow</td>
<td>2001-2003</td>
</tr>
<tr>
<td>Purav Bhatt</td>
<td>Manager, Clinical Development, Medicine Delivery, GSK</td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td>2012-2014</td>
</tr>
<tr>
<td>Christine Trezza</td>
<td>Director, Medical Governance &amp; Operations, Global Medical Affairs, Viiv</td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td>2013-2015</td>
</tr>
<tr>
<td>Kristina Vishnevetskaya</td>
<td>Manager, Oncology Therapeutic Group, Global Regulatory Affairs, GSK</td>
<td>Global Regulatory Affairs fellow</td>
<td>2017-2019</td>
</tr>
<tr>
<td>Hitesh Patel</td>
<td>Medical Information Scientist, Medical Affairs, GSK</td>
<td>Medical Affairs fellow</td>
<td>2017-2019</td>
</tr>
</tbody>
</table>

### Employed at UNC

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Fellowship</th>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denise Rhoney</td>
<td>Associate Dean for Curricular Innovation, PACE, UNC Eshelman School of Pharmacy</td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td>1993-1995</td>
</tr>
<tr>
<td>Craig R. Lee</td>
<td>Associate Professor of Pharmacy, DPET, UNC Eshelman School of Pharmacy</td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td>2000-2002</td>
</tr>
<tr>
<td>Name</td>
<td>Title</td>
<td>Fellowship Dates</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------------------------------------------------------</td>
<td>--------------------------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmacokinetics &amp; Pharmacodynamics</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Pharmacology fellow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patrick Wire</td>
<td>Senior Director, Therapeutic Group, Global Regulatory Affairs, GSK</td>
<td>1994-1996</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Research &amp; Drug Development; Pharmacokinetics fellow</td>
<td>1993-1995</td>
<td></td>
</tr>
<tr>
<td>Melissa Ellis</td>
<td>Director, SERM, Central Safety Department, GSK</td>
<td>1993-1995</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td>1994-1996</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td>1993-1995</td>
<td></td>
</tr>
<tr>
<td>Lakshmi Vasist</td>
<td>Manager, Clinical Pharmacology, GSK</td>
<td>2004-2006</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmacokinetics &amp; Pharmacodynamics fellow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elizaveta Budko</td>
<td>Manager, Therapeutic Group, Global Regulatory Affairs, GSK</td>
<td>2014-2016</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Global Regulatory Affairs fellow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Justin Koteff</td>
<td>Director, Scientific Communications, Strategy &amp; Medical Information, ViV</td>
<td>2009-2011</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bryant Tran</td>
<td>Scientific Director, US Medical Affairs, GSK</td>
<td>2012-2014</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elizabeth Blair</td>
<td>Director, Clinical Development, Scientific Medical Office, ViV</td>
<td>2016-2018</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Research &amp; Drug Development fellow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brittany Dustman</td>
<td>Manager, Oncology Therapeutic Group, Global Regulatory Affairs, GSK</td>
<td>2016-2018</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Global Regulatory Affairs fellow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shivam Patel</td>
<td>Manager, Oncology Therapeutic Group, Global Regulatory Affairs, GSK</td>
<td>2016-2018</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Global Regulatory Affairs fellow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prani Paka</td>
<td>Manager, Global Medical Affairs Oncology, GSK</td>
<td>2016-2018</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical Affairs fellow</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Application and Eligibility

The UNC Eshelman School of Pharmacy and GSK Pharmaceutical Industry Fellowships commence in July 2020. Applicants are highly recommended to attend the ASHP Midyear Clinical Meeting/PPS. Interviews are prearranged and candidates are selected on a competitive basis.

US Medical Affairs, Global Regulatory Affairs and Pharmacokinetics/Pharmacodynamics

The application deadline for early consideration is November 15, 2019.
The final deadline to apply is January 1, 2020. Early applications are highly encouraged.

Visit http://pharmacydpetfellowships.web.unc.edu/ for instructions on submitting an application.